Trending NewsTrending NewsMost-Downgraded StocksMost-DowngradedNASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $563.10 -1.54 (-0.27%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$562.00 -1.10 (-0.20%) As of 07/25/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get REGN alerts:Sign Up Key Stats Today's Range$555.50▼$567.2150-Day Range$483.07▼$614.7952-Week Range$476.49▼$1,211.20Volume755,785 shsAverage Volume906,903 shsMarket Capitalization$60.80 billionP/E Ratio14.34Dividend Yield0.63%Price Target$828.86Consensus RatingModerate Buy Company Overview Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Read More Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreREGN MarketRank™: Regeneron Pharmaceuticals scored higher than 97% of companies evaluated by MarketBeat, and ranked 42nd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 15 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.85% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 5.85% in the coming year, from $35.92 to $38.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 14.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.04.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 14.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.41.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.10. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.16% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 10.84%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRegeneron Pharmaceuticals has a dividend yield of 0.62%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Regeneron Pharmaceuticals is 8.96%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 9.26% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.Read more about Regeneron Pharmaceuticals' dividend. Sustainability and ESG2.3 / 5Environmental Score-2.69 Percentage of Shares Shorted2.16% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 10.84%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.04 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 40 news articles for Regeneron Pharmaceuticals this week, compared to 32 articles on an average week.Search InterestOnly 27 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.MarketBeat Follows26 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 136% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.02% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Stock News Headlines2 Healthcare Stocks That Are Losing to the S&P 500 This YearJuly 27 at 9:15 AM | fool.comRegeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M DealJuly 25 at 11:14 PM | insidermonkey.com[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.July 27 at 2:00 AM | Golden Portfolio (Ad)Bank of America Securities Reiterated a Sell rating on Regeneron Pharmaceuticals (REGN), Lowered the PTJuly 25 at 6:34 PM | insidermonkey.com$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much TodayJuly 25 at 6:34 PM | benzinga.comRegeneron Pharmaceuticals Earnings Preview: What to ExpectJuly 25 at 6:34 PM | finance.yahoo.com3 Low-Volatility Stocks We Steer Clear OfJuly 24 at 2:13 PM | msn.comLongleaf Partners Fund Increased its Holdings in Regeneron Pharmaceuticals (REGN) on a DipJuly 24 at 2:13 PM | msn.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $712.33 at the beginning of the year. Since then, REGN stock has decreased by 20.9% and is now trading at $563.10. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Tuesday, April, 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by $0.61. The company's revenue was down 3.7% on a year-over-year basis. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more. Who are Regeneron Pharmaceuticals' major shareholders? Top institutional investors of Regeneron Pharmaceuticals include Assenagon Asset Management S.A. (0.39%), Swedbank AB (0.21%), Aberdeen Group plc (0.19%) and IMC Chicago LLC. Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi and N Anthony Coles. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings4/29/2025Record date for 6/6 Dividend5/20/2025Ex-Dividend for 6/6 Dividend5/20/2025Dividend Payable6/06/2025Today7/27/2025Next Earnings (Estimated)8/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees15,106Year Founded1988Price Target and Rating Average Price Target for Regeneron Pharmaceuticals$828.86 High Price Target$1,175.00 Low Price Target$547.00 Potential Upside/Downside+47.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$39.28 Trailing P/E Ratio14.34 Forward P/E Ratio15.68 P/E Growth2.1Net Income$4.41 billion Net Margins31.94% Pretax Margin35.38% Return on Equity15.27% Return on Assets11.93% Debt Debt-to-Equity Ratio0.09 Current Ratio4.93 Quick Ratio4.03 Sales & Book Value Annual Sales$14.09 billion Price / Sales4.32 Cash Flow$45.71 per share Price / Cash Flow12.32 Book Value$268.50 per share Price / Book2.10Miscellaneous Outstanding Shares107,965,000Free Float100,386,000Market Cap$60.80 billion OptionableOptionable Beta0.33 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:REGN) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.